GSK ships flu vaccine.
GlaxoSmithKline PLC has begun shipping Fluarix Quadrivalent (influenza vaccine) doses to health care providers in the United states, following licensing and lot-release approval from the FDA's Center for Biologics Evaluation and Research. 'To help our customers meet the flu immunization needs of their patients, GSK has shifted our flu vaccine supply to four-strain (quadrivalent) flu vaccine," said Patrick Desbiens, the company's senior vice president of U.S. vaccines. "This decision gives patients the opportunity for broader protection, since it covers a fourth flu virus strain, compared to bivalent vaccines that only cover three strains. With flu a priority focus of our portfolio, we have made a significant investment in customer service upgrades, which are designed to accelerate delivery time lines to customers."
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||Rx Update|
|Publication:||Chain Drug Review|
|Date:||Aug 10, 2015|
|Previous Article:||Innovative treatment for cholesterol ok'd.|
|Next Article:||Galderma acne drug cleared.|